Implementing the new oral anticoagulants into the hospital formulary

Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate

(2011) Elise S. Eerenberg et al.   CIRCULATION

Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban—an oral, direct and selective factor Xa inhibitor

(2011) Richard C. Becker et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time

(2011) Christian Hesse et al.   THROMBOSIS AND HAEMOSTASIS

Assays for Measuring Rivaroxaban: Their Suitability and Limitations

(2010) Edelgard Lindhoff-Last et al.   THERAPEUTIC DRUG MONITORING

Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay

(2010) Zhaoqing Wang et al.   THROMBOSIS AND HAEMOSTASIS

Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development

(2010) Mike Ufer   THROMBOSIS AND HAEMOSTASIS

Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity

(2010) Joachim Stangier et al.   THROMBOSIS AND HAEMOSTASIS

Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects

(2009) Joachim Stangier et al.   CLINICAL PHARMACOKINETICS

Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans

(2009) C. Weinz et al.   DRUG METABOLISM AND DISPOSITION

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial

(2009) Alexander GG Turpie et al.   LANCET

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

ASHP Guidelines on the Pharmacy and Therapeutics Committee and the Formulary System

(2008) Linda S. Tyler et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans

(2008) N. Raghavan et al.   DRUG METABOLISM AND DISPOSITION

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

(2008) Ajay K Kakkar et al.   LANCET

Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty

(2008) Bengt I. Eriksson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty

(2008) Michael R. Lassen et al.   NEW ENGLAND JOURNAL OF MEDICINE